ArticleNature communications2025
Structure-function relationship of ASH1L and histone H3K36 and H3K4 methylation.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A tryptophan-phenylalanine binding motif for the histone methyltransferases MLL4 and MLL3.The Journal of biological chemistry · 2026Article
- Targeting Ash1L-STING Axis Restores NK Cell Function and Ameliorates Immune-Mediated Bone Marrow Failure Diseases.International journal of biological sciences · 2026Article
- In Vivo Models of Cardiovascular Disease:Biomedicines · 2025Review
- CircSHOC2 regulates steroid hormone synthesis in ovarian granulosa cells through the mir-130b-5p/ASH1L pathway.Zoological research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Kendra R Vann *Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.ORCID http://orcid.org/0000-0002-6366-6112
Rajal Sharma *Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Chih-Chao HsuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Maeva DevoucouxSt-Patrick Research Group in Basic Oncology, Oncology Division of CHU de Québec-Université Laval Research, Laval University Cancer Research Center, Quebec City, Québec, G1R 3S3, Canada.ORCID http://orcid.org/0000-0002-0965-2852
Adam H TencerDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Lei ZengDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0002-4236-6735
Kevin LinDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Li ZhuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Qin LiDepartment of Genetics, University of Pennsylvania, Philadelphia, PA, USA.
Catherine LachanceSt-Patrick Research Group in Basic Oncology, Oncology Division of CHU de Québec-Université Laval Research, Laval University Cancer Research Center, Quebec City, Québec, G1R 3S3, Canada.
Ruben Rosas OspinaDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Qiong TongDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Ka Lung CheungDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Shuai YangDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Soumi BiswasDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Hongwen XuanDepartment of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, 49503, USA.
Jovylyn GatchalianDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Lorena AlamilloDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.ORCID http://orcid.org/0000-0002-2622-0277
Jianlong WangDepartment of Medicine, Columbia Center for Human Development, Columbia University Irving Medical Center, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0002-1317-6457
Suk Min JangSt-Patrick Research Group in Basic Oncology, Oncology Division of CHU de Québec-Université Laval Research, Laval University Cancer Research Center, Quebec City, Québec, G1R 3S3, Canada.
Brianna J KleinDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Yue LuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Patricia ErnstDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Brian D StrahlDepartment of Biochemistry & Biophysics, The University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA.ORCID http://orcid.org/0000-0002-4947-6259
Scott B RothbartDepartment of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, 49503, USA.ORCID http://orcid.org/0000-0003-1631-5392
Martin J WalshDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0001-8339-8285
Michael L ClearyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-7127-3223
Jacques CôtéSt-Patrick Research Group in Basic Oncology, Oncology Division of CHU de Québec-Université Laval Research, Laval University Cancer Research Center, Quebec City, Québec, G1R 3S3, Canada.ORCID http://orcid.org/0000-0001-6751-555X
Xiaobing ShiDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-5242-8189
Ming-Ming ZhouDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. ming-ming.zhou@mssm.edu.ORCID http://orcid.org/0000-0002-7049-0573
Tatiana G KutateladzeDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA. tatiana.kutateladze@cuanschutz.edu.ORCID http://orcid.org/0000-0001-7375-6990
Funding
PW1--A mediator of cell survival by NFKB and cell death by p53P01CA080058 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI AARONSON, STUART A · 2000 to 2016
$20.2MMechanisms of chromatin and transcriptional regulationR35GM126900 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian D Strahl · 2018 to 2026
$5.5MTranscriptional Control of Neuroinflammation in Alzheimer's DiseaseR01AG072562 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, ZHOU, MING-MING · 2021 to 2025
$4.2MMechanism of Transcriptional Regulation of Th2 Cell DevelopmentR01AI177461 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Kalung Cheung, Ming-Ming Zhou · 2023 to 2026
$2.7MTargeting acetylated histone H4 by MLL4R01AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2021 to 2025
$2.1MTranscriptional Mechanism of BRD4 in Solid TumorR01CA239165 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2019 to 2023
$2.0MRole of GAS41 in Human CancerR01CA204020 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2016 to 2020
$2.0MMolecular analysis of ASH1LR01CA252707 · NCI · UNIVERSITY OF COLORADO DENVER · PI TATIANA G KUTATELADZE · 2020 to 2026
$1.9MThe role of JADE in HBO complexesR01HL151334 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.8MHigh Throughput Screen for Inhibitors of the YEATS2 Histone Acylation ReaderR01CA268440 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2022 to 2025
$1.7MMolecular mechanisms of chromatin signaling and epigenetic regulationR35GM152184 · NIGMS · VAN ANDEL RESEARCH INSTITUTE · PI Scott Rothbart · 2024 to 2026
$1.6MAn AVANCE NEO 400 MHz NMR Spectrometer for Chemical Biology and Drug DiscoveryS10OD028504 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2020 to 2020
$599kNCI NIH HHS P01 CA080058NCI NIH HHS R01 CA204020NCI NIH HHS R01 CA239165NCI NIH HHS R01 CA252707NCI NIH HHS R01 CA268440NHLBI NIH HHS R01 HL151334NIAID NIH HHS R01 AI177461NIAID NIH HHS R13 AI124565NIA NIH HHS R01 AG067664NIA NIH HHS R01 AG072562NIA NIH HHS R56 AG067664NIGMS NIH HHS R35 GM126900NIGMS NIH HHS R35 GM152184NIH HHS S10 OD025132NIH HHS S10 OD028504U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA252707U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL151334U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG067664
Abstract
The histone H3K36-specific methyltransferase ASH1L plays a critical role in development and is frequently dysregulated in human diseases, particularly cancer. Here, we report on the biological functions of the C-terminal region of ASH1L encompassing a bromodomain (ASH1L
Indexed as
DNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHistonesTranscription FactorsAnimalsCell DifferentiationDNAEmbryonic Stem CellsHumansMethylationMiceNucleosomesProtein BindingProtein DomainsStructure-Activity RelationshipASH1L protein, humanDNADNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHistonesNucleosomesTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.